Reimbursement Review Reports

( Last Updated : February 3, 2023)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Aloxi (capsule) Palonosetron Chemotherapy-induced nausea and vomiting Withdrawn
Aloxi (injection) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list at the submitted price Complete
Alsitek masitinib mesylate Amyotrophic lateral sclerosis (ALS) Suspended
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension List Complete
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete
Alunbrig Brigatinib NSCLC Do not reimburse Complete
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Alvesco Ciclesonide asthma List Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete